Bath & Body Works, Inc. (NYSE:BBWI) Stock Position Decreased by Oppenheimer & Co. Inc.

Oppenheimer & Co. Inc. lessened its stake in Bath & Body Works, Inc. (NYSE:BBWI - Free Report) by 57.0% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 12,264 shares of the company's stock after selling 16,271 shares during the quarter. Oppenheimer & Co. Inc.'s holdings in Bath & Body Works were worth $475,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. Golden State Wealth Management LLC acquired a new stake in Bath & Body Works during the fourth quarter worth about $26,000. True Wealth Design LLC raised its stake in Bath & Body Works by 5,270.0% during the third quarter. True Wealth Design LLC now owns 1,074 shares of the company's stock worth $34,000 after acquiring an additional 1,054 shares during the period. UMB Bank n.a. raised its stake in Bath & Body Works by 58.8% during the fourth quarter. UMB Bank n.a. now owns 905 shares of the company's stock worth $35,000 after acquiring an additional 335 shares during the period. Wilmington Savings Fund Society FSB acquired a new stake in Bath & Body Works during the third quarter worth about $39,000. Finally, TD Private Client Wealth LLC raised its stake in Bath & Body Works by 24.2% during the third quarter. TD Private Client Wealth LLC now owns 1,697 shares of the company's stock worth $54,000 after acquiring an additional 331 shares during the period. Institutional investors and hedge funds own 95.14% of the company's stock.

Bath & Body Works Stock Down 4.5 %

NYSE:BBWI traded down $1.54 during trading hours on Friday, reaching $32.66. 4,652,756 shares of the company's stock were exchanged, compared to its average volume of 3,886,149. The company has a market capitalization of $7.07 billion, a P/E ratio of 7.97, a price-to-earnings-growth ratio of 0.92 and a beta of 1.89. Bath & Body Works, Inc. has a 12 month low of $26.20 and a 12 month high of $52.99. The business's 50-day simple moving average is $37.37 and its two-hundred day simple moving average is $34.18.

Remove Ads

Bath & Body Works (NYSE:BBWI - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The company reported $2.09 EPS for the quarter, topping analysts' consensus estimates of $2.04 by $0.05. Bath & Body Works had a net margin of 12.43% and a negative return on equity of 44.03%. The firm had revenue of $2.79 billion during the quarter, compared to analyst estimates of $2.78 billion. As a group, sell-side analysts anticipate that Bath & Body Works, Inc. will post 3.3 earnings per share for the current fiscal year.

Bath & Body Works declared that its board has approved a share repurchase program on Thursday, February 27th that permits the company to repurchase $500.00 million in shares. This repurchase authorization permits the company to reacquire up to 6.4% of its shares through open market purchases. Shares repurchase programs are generally a sign that the company's board believes its stock is undervalued.

Bath & Body Works Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, March 7th. Investors of record on Friday, February 21st were paid a $0.20 dividend. This represents a $0.80 dividend on an annualized basis and a yield of 2.45%. The ex-dividend date of this dividend was Friday, February 21st. Bath & Body Works's dividend payout ratio is 21.98%.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the stock. Cowen reiterated a "buy" rating on shares of Bath & Body Works in a research note on Thursday, February 27th. Wells Fargo & Company upgraded shares of Bath & Body Works from an "equal weight" rating to an "overweight" rating and raised their price target for the company from $42.00 to $48.00 in a research note on Friday, January 10th. JPMorgan Chase & Co. set a $47.00 price target on shares of Bath & Body Works in a research note on Thursday, February 27th. Deutsche Bank Aktiengesellschaft raised their price target on shares of Bath & Body Works from $51.00 to $52.00 and gave the company a "buy" rating in a research note on Tuesday, November 26th. Finally, Barclays dropped their price target on shares of Bath & Body Works from $43.00 to $38.00 and set an "equal weight" rating on the stock in a research note on Monday, March 3rd. Five equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. Based on data from MarketBeat.com, Bath & Body Works presently has a consensus rating of "Moderate Buy" and a consensus price target of $45.06.

Bath & Body Works Profile

Bath & Body Works, Inc is a specialty retailers and home to America's Favorite Fragrances, offering a breadth of exclusive fragrances for the body and home, including the selling collections for fine fragrance mist, body lotion and body cream, 3-wick candles, home fragrance diffusers and liquid hand soap.